New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
10:25 EDTSNY, SNY, SNY, SGEN, SGEN, SGEN, RHHBY, RHHBY, RHHBY, PCYC, PCYC, PCYC, NVS, NVS, NVS, MRK, MRK, MRK, JNJ, JNJ, JNJ, INFI, INFI, INFI, IMGN, IMGN, IMGN, GILD, GILD, GILD, CELG, CELG, CELG, BMY, BMY, BMY, BLUE, BLUE, BLUE, AMGN, AMGN, AMGN, ABBV, ABBV, ABBVLeerink pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts provide an update on GU cancer, in conjunction with the upcoming ASCO Annual Meeting, where relevant companies ABBV, AMGN, BLUE, BMY, CELG, GILD, IMGN, INFI, JNJ, MRK, NVS, PCYC, RHHBY, SGEN and SNY may be discussed on the Analyst/Industry conference call to be held on May 23 at 11 am.
News For ABBV;AMGN;BLUE;BMY;CELG;GILD;IMGN;INFI;JNJ;MRK;NVS;PCYC;RHHBY;SGEN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 8, 2015
07:24 EDTJNJNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
05:30 EDTABBVEnanta announces data on regimens containing protease inhibitors paritaprevir
Subscribe for More Information
April 7, 2015
17:58 EDTGILDGilead submits NDA for investigational combination for treatment of HIV-1
Subscribe for More Information
16:00 EDTGILDOptions Update; April 7, 2015
Subscribe for More Information
07:31 EDTABBVBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.
07:14 EDTRHHBY, BMY, MRK, NVS, SNYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
16:17 EDTBMYOn The Fly: Closing Wrap
Subscribe for More Information
14:34 EDTJNJDepomed price target raised to $30 from $27 at Roth Capital
Subscribe for More Information
12:44 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
12:13 EDTBMYuniQure price target raised to $40 from $35 at Piper Jaffray
Subscribe for More Information
09:36 EDTJNJActive equity options trading on open
Subscribe for More Information
08:13 EDTNVSJuno Therapeutics announces patent litigation settlement
Subscribe for More Information
08:13 EDTBMYCelldex announces initiation of Phase 1/2 study of Varlilumab combination
Subscribe for More Information
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.
07:33 EDTBMYBristol-Myers announces strategic collaboration with uniQure
Subscribe for More Information
06:21 EDTJNJJohnson & Johnson CEO comments on Asia expansion, WSJ reports
Subscribe for More Information
05:19 EDTAMGNAmgen announces EC approval of Vectibix in combination with Folfiri
Subscribe for More Information
April 5, 2015
14:43 EDTGILDActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use